

ASX Announcement

Recce calls for Australian investment in R&D to develop new antibiotics on the back of initiatives

SYDNEY Australia 19 April 2017: Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics to treat serious infections, today welcomed calls by the Australasian Society for Infectious Diseases and the Australian Medical Association for Australia to do more to address the growing problem of bacterial resistance to antibiotics.

Recce Limited Executive Chairman Dr Graham Melrose said, "We are encouraged to see such a broad range of organisations and companies committing to address the issue of bacterial resistance to antibiotics. It reinforces our focus and efforts to bring our promising new synthetic antibiotic to market as soon as possible."

Recce is the most advanced company in Australia progressing a novel class of antibiotics towards human clinical trials. It is currently completing its pre-clinical development program by submitting its RECCE® 327 to the FDA in the USA for approval to start a Phase I clinical study. It anticipates its first indication being to treat resistant bacteria causing to Sepsis.

In an [editorial published in the Medical Journal of Australia](#), the President of the Australasian Society for Infectious Diseases, Professor Cheryl Jones warned of the dangers of not urgently addressing the issue.

Welcoming the call to action from across industry, governments and public-sector funded organisations and initiatives, Dr Melrose said "Any way that we can stem the rapid rise in bacterial resistance to the current arsenal of antibiotics is of course very welcome. However, resistance is already with us, and what we urgently need in the medium and longer term is investment in R&D that can deliver a pipeline of new antibiotics for the future."

Dr Melrose noted that resistance is a natural phenomenon and that due to a lack of investment in R&D by Governments and drug companies there has been no completely new class of antibiotic launched for over thirty years, and it takes over a decade to get a new antibiotic from start in the lab to new drug approval".



ASX: RCE

Head Office - Perth Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899
Sydney Office Level 34, 50 Bridge Street, AMP Centre, SYDNEY NSW 2000 **T** +61 (0)2 8216 0768 **F** +61 (0)2 8216 0701
Washington Office 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

The Australian Medical Association has called for the establishment of an Australian National Centre for Disease Control, similar to the US Centers for Disease Control and Prevention, with a focus on current and emerging disease threats.

“Epidemiological monitoring is extremely helpful in containing outbreaks and in helping to direct resources where the problem of resistance is greatest” said Dr Melrose, noting that Recce has already demonstrated *in vitro* or *in vivo* animal efficacy against seven of the top 12 [priority list of antimicrobial resistant bacteria](#) highlighted in a report published recently by the World Health Organisation (WHO).

In other countries, initiatives have been launched to support R&D into the development of new antibiotics, such as [CARB-X](#), whose mission is to protect humanity from the most serious bacterial threats by accelerating antibacterial product development over the next 25 years. With US\$500 million to invest from the US [BARDA](#) and the UK [Wellcome Trust](#) and the [AMR Centre](#), CARB-X has already invested in ten US and UK companies of which only three are developing new classes of antibiotics. “We would welcome similar initiatives in Australia to support the development of new antibiotics by Australian companies” said Dr Melrose.

About Recce Ltd

Recce Ltd (ASX: RCE) is a world-leader in synthetic-polymer compounds, particularly against all bacteria, and viruses. The RECCE® polymers have been synthesized by an extremely economic method. RECCE® polymers have shown in laboratory tests that they have continued activity against bacteria, including superbugs, even after repeated use. Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes, and the development of the manufacture of RECCE® 327. Recce has granted patents in Australia, United States, Europe, Japan and China – giving it legal monopolies, and potential financial returns, from manufacture and distribution of its products in about 80% of the world’s pharmaceutical markets for antibiotics.

To receive the latest information on Recce - [Subscribe here](#)



For further information please visit www.recce.com.au or contact:

Investor Relations

Peter Williams
CFO & Company Secretary
Recce Ltd
Tel: (08) 9253 9800

Media (Australia)

Andrew Geddes
CityPR
Tel: (02) 9267 4511

Media (International)

Sue Charles/Daniel Gooch
Instinctif Partners
Tel: +44 (0)20 7866 7905
E: recce@instinctif.com

